Zacks Investment Research upgraded shares of TiGenix – American Depositary Shares (NASDAQ:TIG) from a hold rating to a buy rating in a report issued on Friday morning. Zacks Investment Research currently has $26.00 price objective on the stock.
According to Zacks, “TiGenix NV is a biopharmaceutical company. It focused on developing and commercializing novel therapeutics for allogeneic or donor-derived, expanded stem cells. The company’s product platform consists of Cx601 and Cx611 which are in clinical trial stage. It operates primarily in Madrid, Spain. TiGenix NV is based in Leuven, Belgium. “
A number of other brokerages also recently issued reports on TIG. Canaccord Genuity reiterated a buy rating and issued a $30.00 price target (up previously from $22.00) on shares of TiGenix – American Depositary Shares in a report on Wednesday, September 20th. BidaskClub upgraded shares of TiGenix – American Depositary Shares from a strong sell rating to a sell rating in a report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. TiGenix – American Depositary Shares currently has a consensus rating of Hold and an average price target of $29.27.
An institutional investor recently bought a new position in TiGenix – American Depositary Shares stock. EAM Investors LLC bought a new stake in shares of TiGenix – American Depositary Shares (NASDAQ:TIG) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned approximately 1.20% of TiGenix – American Depositary Shares at the end of the most recent quarter. 5.31% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2018/01/09/tigenix-american-depositary-shares-tig-raised-to-buy-at-zacks-investment-research.html.
TiGenix – American Depositary Shares Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.